KHPG(SZ:002773)2022-12-03 10:10Group 1: Financial Performance and Distribution - The proposal for the profit distribution and capital reserve increase was approved at the board meeting on April 26, 2019, and the shareholders' meeting on May 20, 2019 [4] - The specific date for the rights registration is being coordinated with relevant departments, and further announcements will be made [4] - The company experienced a significant increase in inventory in 2018, attributed to operational needs [5] Group 2: Market and Sales Insights - The sales of traditional Chinese medicine saw a decline in 2018, and the company is working towards recovery [5][11] - The company is actively expanding its market presence and is progressing according to its plans [8] - The revenue share from traditional Chinese medicine has decreased significantly compared to 2017 due to changes in marketing strategies and related policies [10][11] Group 3: Clinical Trials and International Operations - The company has invested $228 million over eight years for Phase III clinical trials in the U.S. and Europe, with significant progress reported [10][11] - The international multi-center Phase III clinical research has received approvals in 25 countries or regions, with over 200 research centers involved [10][11] Group 4: Corporate Governance and Shareholding - The major shareholder's stake is approximately 70%, while another fund holds about 10% of the shares, facing liquidation due to fund expiration [11][12] - The company is committed to optimizing its corporate governance structure in accordance with legal requirements [12]